Genmab — April 2020
-
Den kan de da ikke spinde rundt til noget positivt
-
Svar på det retrospektive skriv fra forleden, der anførte højere dødelighed i HCQ grupperne https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Response-to-Magagnoli.pdf
-
one should only trade on Genmab rumours from @GeorgeBest
-
Hope we will also get facts soon
-
We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results. Furthermore, we believe the post included inappropriate characterizations of the study. forts.
-
Importantly, because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease. forts.
-
We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future. There are multiple ongoing Phase 3 studies that are designed to provide the additional data needed to determine the potential for remdesivir as a treatment for COVID-19. These studies will help inform whom to treat, when to treat and how long to treat with remdesivir. forts.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind